Cytosorbents Schedules Key FDA Pre-Submission Meetings for DrugSorb-ATR Programs

summarizeSummary

Cytosorbents announced it has scheduled two pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs for DrugSorb-ATR, marking a key step in its regulatory path.

check_boxKey Events · Product Development and Regulatory · CTSO

• FDA Pre-Submission Meetings Scheduled

  Cytosorbents will hold two pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs for DrugSorb-ATR.

• Addressing Prior Regulatory Setbacks

  One meeting will focus on generating additional mechanistic data required for a new De Novo submission for the ticagrelor program, following a prior denial.

• Advancing DOAC Indication

  A separate meeting will review existing data for the DOAC indication to determine requirements for a parallel De Novo submission, consistent with its Breakthrough Device Designation.

• Critical for Future Growth

  These steps are crucial for DrugSorb-ATR to gain potential U.S. and Canadian marketing approval, which is vital for the company's long-term growth and financial stability amidst ongoing challenges.

auto_awesomeAnalysis · CTSO · Industrial Applications And Services

Cytosorbents has scheduled two critical pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs for DrugSorb-ATR. These meetings are a vital step in addressing previous regulatory setbacks and advancing the company's investigational device towards potential U.S. marketing approval. Given the company's ongoing financial challenges, including a going concern warning and Nasdaq delisting risk, progress on its core product pipeline is essential for its long-term viability and growth.